Greater Celandine

Greater Celandine contains over 70 bioactive compounds dominated by benzylisoquinoline alkaloids—including chelidonine, sanguinarine, berberine, and coptisine at concentrations of 0.27–2.25% in aerial parts and up to 4% in roots—which mediate its hepatoprotective, antispasmodic, and antimicrobial effects through alkaloid-driven enzyme inhibition and membrane disruption. A recently characterized antimicrobial peptide, CM-AMP1, achieved nearly 100% activity against both E. coli ATCC 25922 and methicillin-resistant Staphylococcus aureus USA300 LAC in preclinical peptide library screens, though no controlled human clinical trials have confirmed therapeutic efficacy or established safe therapeutic dosing.

Origin & History

Chelidonium majus is native to Europe and western Asia, growing abundantly along roadsides, hedgerows, forest margins, and disturbed soils from the British Isles eastward through Russia and into East Asia. It thrives in nitrogen-rich, moderately moist soils with partial shade, typically found at elevations from sea level to approximately 1,600 meters. The plant has been introduced and naturalized across North America and parts of the Southern Hemisphere, where it grows as a cosmopolitan weed requiring minimal cultivation.

Historical & Cultural Context

Chelidonium majus has been documented in European herbalism since antiquity; Dioscorides described it in De Materia Medica (1st century CE) as a plant useful for eye ailments and liver disease, and its common name derives from the Greek 'chelidon' (swallow), reflecting the folk belief that swallows used its sap to restore their chicks' sight. In Eastern European traditional medicine, particularly within Russian, Polish, and Ukrainian folk healing, the plant's bright orange latex was applied topically for wart removal, skin papillomas, and fungal infections, while decoctions of aerial parts were consumed as liver tonics and antispasmodics for gallbladder colic. Medieval European herbalists, including those contributing to the Circa Instans and later Gerard's Herball (1597), classified it as a potent cholagogue and credited it with treating jaundice, a use consistent with the alkaloid-mediated bile-flow stimulation now studied pharmacologically. The plant also has a documented, if controversial, history in Russian oncology under the proprietary preparation 'Ukrain,' a semi-synthetic thiophosphoric acid conjugate of Chelidonium alkaloids that was studied in Eastern European clinical settings in the late 20th century, though independent replication of those results remained limited.

Health Benefits

- **Hepatoprotective Activity**: Alkaloids including chelidonine and berberine, alongside flavonoids such as rutin and quercetin, are thought to protect hepatocytes from oxidative and toxic insults; in vitro and animal studies suggest anti-inflammatory and antifibrotic effects, although human data remain absent.
- **Antispasmodic Effects**: Chelidonine specifically exhibits smooth muscle relaxant properties by modulating calcium-dependent contractile pathways in biliary and gastrointestinal tissues, supporting traditional use for gallbladder spasm and digestive cramping.
- **Antimicrobial Activity**: The cysteine-rich peptide CM-AMP1 (25 amino acids, stabilized by three disulfide bonds) exerts membrane-lytic killing against both Gram-negative E. coli and MRSA in preclinical assays, while quaternary alkaloids such as sanguinarine and berberine contribute broad-spectrum antibacterial action through DNA intercalation and membrane disruption.
- **Anticancer Potential**: Sanguinarine and chelerythrine induce apoptosis and inhibit proliferation in multiple cancer cell lines in vitro by generating reactive oxygen species and interfering with topoisomerase activity, though no human oncology trials have been conducted.
- **Antioxidant Properties**: Phenolic acids including chelidonic acid, caffeic acid, and ferulic acid, plus flavonoids quercetin and kaempferol, contribute free-radical scavenging capacity that is biochemically independent of the alkaloid fraction, as confirmed in extract-fractionation antioxidant studies.
- **Digestive and Biliary Tonic**: Traditional Eastern European phytomedicine employs the herb as a cholagogue and choleretic, with alkaloid-driven stimulation of bile flow proposed to assist fat emulsification and relieve biliary sluggishness; this mechanism remains mechanistically plausible but clinically unvalidated.
- **Antiviral Preliminary Activity**: Chelidonine and related protoberberine alkaloids have demonstrated inhibitory activity against select RNA viruses in cell-culture models, attributed to interference with viral replication enzymes, though this area of research is in its earliest stages.

How It Works

The primary alkaloids of Chelidonium majus—chelidonine, sanguinarine, berberine, and coptisine—belong to the benzylisoquinoline class and exert effects through multiple overlapping molecular targets: sanguinarine and chelerythrine intercalate into DNA and inhibit topoisomerase I/II, disrupting replication in rapidly dividing cells, while berberine modulates AMP-activated protein kinase (AMPK) signaling and inhibits NF-κB transcriptional activity to produce anti-inflammatory and hepatoprotective outcomes. Chelidonine relaxes smooth muscle by interfering with voltage-gated calcium channels and reducing intracellular Ca²⁺ mobilization, which mechanistically underpins the antispasmodic effects observed in biliary and intestinal tissue preparations. The antimicrobial peptide CM-AMP1 acts through a membrane-lytic mechanism confirmed by quantitative proteomics: sub-lethal exposure of E. coli to CM-AMP1-containing fractions upregulated membrane-stress-response proteins, and alkylation of its six cysteine residues—which form three stabilizing disulfide bonds—markedly reduced antimicrobial potency, confirming that intact tertiary structure is essential for membrane insertion and disruption. Antioxidant activity, mediated by phenolic acids and flavonoids rather than alkaloids, operates through direct radical scavenging and metal chelation, representing a mechanistic pathway distinct from the alkaloid-dominated pharmacological profile.

Scientific Research

The evidence base for Chelidonium majus consists almost entirely of in vitro biochemical assays, phytochemical characterization studies, and limited animal experiments, with no published randomized controlled trials reporting sample sizes or effect sizes in human subjects. Preclinical peptide library screening identified CM-AMP1 as achieving approximately 100% antimicrobial efficacy against E. coli ATCC 25922 (relative to 100 µg/mL ampicillin) and MRSA USA300 LAC (relative to 100 µg/mL erythromycin), representing compelling but early-stage data requiring validation in animal infection models and subsequent human trials. Alkaloid-focused studies have characterized over 70 compounds and their in vitro bioactivities against cancer cell lines, bacteria, and hepatocyte models, but translation to human pharmacodynamics is constrained by the absence of pharmacokinetic data, bioavailability measurements, and dose-response studies in humans. Regulatory authorities in Germany (BfArM) and the European Medicines Agency have documented hepatotoxicity case reports linked to Chelidonium-containing products, which has significantly tempered enthusiasm for clinical development and highlights an urgent need for rigorous safety-focused human studies before therapeutic claims can be substantiated.

Clinical Summary

No prospective clinical trials with defined sample sizes, primary endpoints, or reported effect sizes have been published for Chelidonium majus in human subjects as captured in current research databases. The most quantified preclinical outcome is CM-AMP1's near-complete antimicrobial efficacy against reference bacterial strains in peptide library assays; alkaloid and extract studies produce in vitro data on hepatoprotective and anticancer activity without translational clinical confirmation. Regulatory hepatotoxicity signals from post-marketing surveillance in Europe—including cases of acute hepatitis associated with standardized Chelidonium extracts—represent the most clinically significant human data available, though causality and dose-dependency have not been rigorously established in prospective designs. Confidence in any therapeutic benefit claim remains very low given the preclinical-only evidence base, and confidence in the hepatotoxicity risk signal is moderate, derived from pharmacovigilance case series rather than controlled observation.

Nutritional Profile

Chelidonium majus is not a significant source of macronutrients and is not consumed as a food; its nutritional profile is characterized by its phytochemical composition rather than caloric contribution. Benzylisoquinoline alkaloids constitute 0.27–2.25% of dry aerial parts and up to 3–4% of root dry weight, with chelidonine, sanguinarine, berberine, coptisine, protopine, chelerythrine, and magnoflorine among the quantified constituents. Flavonoids including rutin, quercetin, and kaempferol are present alongside phenolic acids (chelidonic acid, caffeic acid, ferulic acid) that contribute measurable antioxidant capacity independent of alkaloid content. The plant accumulates 24 macro- and microelements including aluminum, calcium, iron, potassium, and magnesium; phytosterols (notably α-spinasterol), choline, tyramine, histamine, saponosides, and polysaccharides round out a chemically complex matrix. Bioavailability of alkaloids from oral preparations is poorly characterized; no human pharmacokinetic studies document absorption rates, plasma half-lives, or tissue distribution for the major alkaloids.

Preparation & Dosage

- **Dried Herb (Traditional Infusion)**: 1–2 g of dried aerial parts steeped in 150 mL hot water for 10–15 minutes, taken 2–3 times daily; this is a traditional Eastern European preparation for biliary complaints, not validated by clinical trials.
- **Liquid Extract (1:1 in 25% ethanol)**: Historically 1–2 mL taken 2–3 times daily; alkaloid content is highly variable and not standardized across commercial products.
- **Standardized Dry Extract**: Some European products historically standardized to 4–6 mg total alkaloids per dose unit; however, such products have faced regulatory scrutiny and withdrawal in several EU countries due to hepatotoxicity concerns.
- **Tincture (1:5 in 45% ethanol)**: 2–4 mL up to three times daily was used in traditional Western herbal medicine; the dilution reduces but does not eliminate alkaloid exposure.
- **Research-Grade Fractionation**: In laboratory settings, bioactive enrichment employs strong cation exchange (SCX) chromatography followed by reversed-phase HPLC to isolate alkaloid and peptide fractions; these methods are not applicable to self-administration.
- **Important Dosing Caveat**: No clinically validated therapeutic dose has been established; given hepatotoxicity reports, prolonged use (beyond 4 weeks) is strongly discouraged without medical supervision, and no maximum safe dose has been formally determined in human studies.

Synergy & Pairings

Traditional Eastern European formulations frequently combine Chelidonium majus with Silybum marianum (milk thistle), whose silybin and silymarin constituents provide complementary hepatoprotection through antioxidant and anti-inflammatory pathways that may partially offset Chelidonium's hepatotoxic alkaloid burden, though this combination has not been rigorously tested in controlled trials. Berberine-containing herbs such as Berberis vulgaris (barberry) share overlapping protoberberine alkaloids with Chelidonium and may produce additive antibacterial and anti-inflammatory effects via synergistic NF-κB suppression, but additive toxicity risk must also be considered. Phenolic-rich herbs including artichoke leaf (Cynara scolymus) are sometimes co-formulated in European digestive bitters to enhance choleretic and antioxidant activity, with quercetin from both sources potentially offering complementary free-radical scavenging independent of alkaloid content.

Safety & Interactions

Chelidonium majus carries a clinically meaningful hepatotoxicity risk: multiple case reports and pharmacovigilance reviews from Germany, Belgium, and other EU countries document acute cholestatic or cytolytic hepatitis in patients using standardized Chelidonium extracts, leading to regulatory actions including product withdrawal and label warnings; the hepatotoxic mechanism is not fully elucidated but may involve reactive alkaloid metabolites. High alkaloid concentrations—particularly sanguinarine and chelerythrine, which are cytotoxic at micromolar concentrations in cell models—present theoretical risks of mutagenicity and cytotoxicity at suprapharmacological doses, and the plant's orange latex is an irritant to skin and mucous membranes on direct contact. Potential drug interactions include additive hepatotoxic risk with acetaminophen, statins, azole antifungals, and other hepatically metabolized drugs; berberine-class alkaloids can inhibit cytochrome P450 3A4 and P-glycoprotein, which may alter plasma levels of co-administered medications including immunosuppressants, anticoagulants, and antiretrovirals. Chelidonium majus is contraindicated in pregnancy (uterotonic alkaloid activity), lactation, pre-existing liver disease, and in patients with bile duct obstruction; use in children is not established, and self-medication for longer than four weeks is inadvisable without hepatic monitoring.